Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$132 Mln
P/E Ratio
--
P/B Ratio
71.18
Industry P/E
--
Debt to Equity
0.04
ROE
-1.81 %
ROCE
-137.57 %
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-106.83 Mln
EBITDA
$-130.10 Mln
Net Profit
$-138.53 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Tiziana Life Sciences - ADR
| 88.16 | 18.02 | 64.39 | 73.83 | 9.42 | 1.43 | -- |
|
BSE Sensex*
| 2.00 | 3.78 | 4.30 | 8.24 | 11.75 | 20.16 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|
|
Tiziana Life Sciences - ADR
| -6.43 | -37.50 | -52.48 | 87.04 | -27.52 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 20.88 | 1,456.52 | -- | -9.85 |
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. The company's lead product candidate in immunology is Foralumab... (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom. Address: 14/15 Conduit Street, London, United Kingdom, W1S 2XJ Read more
Founder, Executive Chairman & Interim CEO
Mr. Gabriele Marco Antonio Cerrone M.B.A.
Founder, Executive Chairman & Interim CEO
Mr. Gabriele Marco Antonio Cerrone M.B.A.
Headquarters
London
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Tiziana Life Sciences Ltd - ADR stood at $ 12 Mln as on 31-Dec-23
The share price of Tiziana Life Sciences Ltd - ADR is $1.31 (NASDAQ) as of 23-Apr-2025 16:13 EDT. Tiziana Life Sciences Ltd - ADR has given a return of 9.42% in the last 3 years.
Tiziana Life Sciences Ltd - ADR has a market capitalisation of $ 132 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Tiziana Life Sciences Ltd - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Tiziana Life Sciences Ltd - ADR and enter the required number of quantities and click on buy to purchase the shares of Tiziana Life Sciences Ltd - ADR.
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom. Address: 14/15 Conduit Street, London, United Kingdom, W1S 2XJ
The CEO & director of Mr. Gabriele Marco Antonio Cerrone M.B.A.. is Tiziana Life Sciences Ltd - ADR, and CFO & Sr. VP is Mr. Gabriele Marco Antonio Cerrone M.B.A..
There is no promoter pledging in Tiziana Life Sciences Ltd - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
153
|
| Tiziana Life Sciences Ltd. - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-140.92
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Tiziana Life Sciences Ltd - ADR was $-11 Mln.
$0.15
(
